Data

Copy and paste the text below. It is read-only. Select All

__ metabolism hepatic __; __threshold for __ NNRTIs, low, resistance pill buredn/lack of potency delavirdine (rescriptor) inducer nevirapine (viramune) inducer and inhibitor efavirenz (sustiva), etravirine (intelence) cyp 450 3a4 substrate rilpivirine all have __ and ___ hepatotoxicity and rash __contraindicated in women with pretreatment CD4 >__; men >__, or pts coinfected with __ nevirapine, 250, 400, hep b or c CNS and psychiatric ARDs efavirenz (sustiva) take at bedtime on empty stomach efavirenz (sustiva) caution in ppl with serious mental health illness efavirenz (sustiva) pregnancy category D efavirenz nevirapine (viramune): concern of ___ stevens-johnson dose titration: 200mg for 14 days, then 400mg nevirapine (viramune) next generatino NNRTI etravirine (intelence) __: newly approved NNRTI for ARV __ pts rilpivirine (edurant), naive ___: ARV naive patients (HIV-RNA viral load <___) rilpivirine (edurant), 100,000 requires acidic pH rilpivirine (edurant) avoid PPI rilpivirine (edurant) once daily dosing rilpivirine (edurant) fewer adverse effects (than efavirenz) rilpivirine (edurant) potential cross resistance with etravirine rilpivirine (edurant) co-formulated with tenofovir and emtricitabine rilpivirine (edurant)